Objective: To analyze docetaxel (T) and carboplatin (C) combined with trastuzumab (H) -TCH regimen as neoadjuvant systemic therapy in early breast cancer patients with human epidermal growth factor receptor 2 (HER-2) positive. Methods: From January 2008 to December 2014, the data of patients diagnosed as early breast cancer in Breast Disease Center of Peking University First Hospital were retrospective reviewed. The data of patients with HER-2 positive conducted TCH neoadjuvant therapy and surgery, and with the complete clinicopathological information were analyzed. Results: A total of 77 cases were enrolled in this study. We defined G2+ G3+ G4+ G5 as responsive group according to Miller-Payne grading system, the responsive rate was 84.4% (65/77). The rate of complete pathological remission (pCR) was 39.0% (30/77). The 5-year disease free survival (DFS) was 87.3%, and 5-year overall survival (OS) was 93.6%. There was a significant difference between DFS and OS in the responsive group and non-responsive group (DFS: χ2=6.762, P=0.009; OS: χ2=5.062, P=0.024). Conclusion: TCH is an effective neoadjuvant therapy for patients with HER-2 positive breast cancer, and the toxic and side effects were under control.
目的： 探讨人类表皮生长因子受体2(HER－2)阳性早期乳腺癌患者采用多西他赛(docetaxel，T)、卡铂(carboplatin，C)联合曲妥珠单抗(trastuzumab，H)(TCH)方案新辅助治疗后的临床疗效。 方法： 选择2008年1月至2014年12月北京大学第一医院乳腺疾病中心实施TCH新辅助化疗并接受手术的HER－2阳性早期乳腺癌患者进行回顾性研究，并结合术后病理疗效评价进行预后分析。 结果： 共计77例临床病理资料及随访信息完整的患者进入本研究。其中，病理疗效评价有效率(G2＋G3＋G4＋G5)84.4%。病理完全缓解率(pCR)39.0%(30/77)。5年无病生存率(DFS)87.3%，5年总生存率(OS)93.6%，病理评价有效与无效患者的DFS与OS差异均有统计学意义(DFS：χ2＝6.762，P＝0.009；OS：χ2＝5.062，P＝0.024)。 结论： TCH方案是HER－2阳性乳腺癌患者有效的新辅助治疗方案，毒副反应可控。.
Keywords: Breast neoplasms; HER-2 positive; Neoadjuvant therapy; TCH regimen.